New cocktail aims to shrink untouchable liver tumors into surgical candidates
NCT ID NCT07483359
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs—chemotherapy infused directly into the liver, a targeted pill, and an immunotherapy—in 38 people with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tumor enough so that surgeons can remove it completely. Participants will receive treatment for up to 6 cycles, and researchers will measure how many become eligible for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FOLFOX-HAIC (chemotherapy infusion), lenvatinib (targeted therapy), and tislelizumab (immunotherapy)
- What this could lead to
- If successful, this combination could shrink advanced liver tumors enough to allow surgical removal, potentially improving long-term survival for patients who currently have few options.
- What could go wrong
- This is a small, early-phase study (38 people) with no control group, so results may not apply broadly. The drugs can cause serious side effects like liver damage, bleeding, or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?